UNSPSC 51112200: Combination antineoplastics

This classification denotes combination drugs that inhibit or prevent the proliferation of neoplasms, or proliferation of new abnormal growths of tissue, and which are therefore called ANTI-NEOPLASTICS or ANTINEOPLASTICS. Typical combination antineoplastic constituents are bleomycin, cyclophosphamide, doxorubicin, ifosfamide, methotrexate, and sodium chloride.

UNSPSC 51112200 Combination antineoplastics is a Class code covering chemotherapy drug combinations and related pharmaceutical products procured by state and local health agencies. The Texas Health and Human Services Commission's April 2026 Request for Information (RFI) on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program illustrates the scope: state health systems and pharmacy benefit programs are evaluating vendors' capacity to supply pharmaceuticals directly from manufacturers rather than through traditional pharmacy benefit managers, group purchasing organizations, or wholesalers. State and local procurement under this code centers on health departments, Medicaid agencies, corrections systems, and employee health plans seeking to source specialty pharmaceuticals—including combination chemotherapy regimens—with negotiated net pricing, value-based arrangements, and direct fulfillment models that bypass conventional intermediary channels.

The recent activity identified is limited to Texas HHS's exploratory RFI with an April 3, 2026 response date, which indicates early-stage market research rather than a committed procurement award. The RFI seeks vendor experience with direct contracting for self-insured employers and government health plans, flexible pricing negotiation without rebate structures, and outcomes-based payment options, but no budget allocation, set-aside designation, or award timeline was specified. Geographic activity appears concentrated in Texas at this time, with the source supporting no additional state or local opportunities under this code. The RFI represents a preliminary information-gathering phase designed to inform future formal solicitations; no contract values or vendor awards have been announced.